The race to solve the obesity crisis isn’t simply about finding a drug that works—it’s about establishing which drug works best, and the latest data suggests Eli Lilly is currently winning. The pharmaceutical landscape shifted dramatically this week following the release of phase three trial results for Novo Nordisk’s CagriSema, a combination drug intended to surpass its blockbuster Wegovy. While the results aren’t failures—patients did lose weight—they fall short of the efficacy demonstrated by Lilly’s Zepbound, raising serious questions about CagriSema’s commercial viability and forcing a reassessment of Novo Nordisk’s strategy. This isn’t just a financial setback for one company; it’s a critical moment for understanding how the market will prioritize increasingly effective, but also increasingly complex, obesity treatments.
The Weight of Expectation: Trial Results and Market Response
The core of the issue lies in the comparative weight loss achieved. The 84-week trial data revealed that CagriSema prompted an average weight loss of 23% in participants. While Martin Holst Lange, Novo Nordisk’s Chief Scientific Officer, emphasized this as “clinically meaningful additive weight loss effects” exceeding those seen with GLP-1 targeting drugs alone (like Wegovy), it’s demonstrably less than the approximately 25% weight loss observed in the Zepbound trial. This seemingly small difference – roughly 2 percentage points – triggered a significant market reaction, with Novo Nordisk shares plummeting on Monday. Financial analysts were quick to weigh in, with Evan Seigerman of BMO stating bluntly, “We struggle to identify a reason why a patient would be prescribed CagriSema” instead of Zepbound. Chris Schott of JPMorgan echoed this sentiment, predicting difficulty for CagriSema to gain market share and confirming Zepbound’s position as a “clear market leader.” It’s important to note that these assessments aren’t based on a rejection of CagriSema’s efficacy in absolute terms, but rather on its relative performance against a competitor already establishing dominance.
See the original CNBC story for the full account.
Beyond the Numbers: What the Data Actually Shows
The narrative circulating often frames this as a simple “loss” for Novo Nordisk, but a closer look reveals a more nuanced picture. CagriSema combines semaglutide (the active ingredient in Wegovy) with cagrilintide, a novel hormone affecting appetite. The fact that it did demonstrate superior results to semaglutide alone is a positive finding, suggesting the combination approach holds promise. Furthermore, Mike Doustdar, Novo Nordisk’s CEO, dismissed concerns, even calling the 23% weight loss “fantastic” and questioning the “abnormality” of Zepbound’s 25% result. This highlights a key tension: Novo Nordisk is actively framing CagriSema as a valuable addition to the treatment landscape, even while analysts question its competitive edge. Doustdar also pointed to the potential for higher doses of CagriSema to yield results comparable to Wegovy’s high-dose formulation, which achieves around 21% weight loss. This suggests the company is already pivoting to explore dose optimization as a potential solution.
Limitations to Consider: Trial Design and Future Prospects
It’s crucial to acknowledge the limitations inherent in comparing trial data across different studies. While both trials assessed weight loss over 84 weeks, subtle differences in patient populations, study design, and data analysis methods could contribute to the observed variations. The fact that Novo Nordisk has already submitted CagriSema for FDA approval, anticipating a decision in late 2026, underscores their continued belief in the drug’s potential. The upcoming REDEFINE 11 trial, comparing CagriSema to a placebo in 600 adults with obesity, will provide further data, though Evan Seigerman of BMO expressed skepticism that it will “change the narrative.” A phase three trial investigating higher doses of CagriSema, planned for the latter half of 2026, is also critical. However, the success of these trials isn’t guaranteed, and the market is already anticipating the launch of Lilly’s next-generation drug targeting three gut hormones, which has demonstrated even greater weight loss – over 28% in clinical trials.
The Broader Implications: Beyond Individual Drugs
The CagriSema situation underscores a critical shift in the obesity treatment paradigm. The initial excitement surrounding GLP-1 agonists like Wegovy is now being tempered by the emergence of more potent, multi-hormonal therapies. Novo Nordisk recognizes this, having invested $2 billion in a Chinese drugmaker’s experimental medicine with a similar mechanism to Lilly’s upcoming treatment, and Mike Doustdar has indicated a willingness to pursue further acquisitions. The question now isn’t simply whether CagriSema will succeed, but whether Novo Nordisk can adapt quickly enough to maintain its position in a rapidly evolving market. Investors and patients alike should watch closely for the results of the REDEFINE 11 and higher-dose CagriSema trials, but perhaps more importantly, they should anticipate a continued escalation in the efficacy benchmarks for obesity drugs – and consider whether the pursuit of ever-greater weight loss comes with unforeseen risks or side effects.
